ストックスクリーナーアプリを入手
0.68
2.88%
-0.0202
Ocugen Inc (OCGN) 最新ニュース
Ocugen to Announce Q4 and Full-Year 2024 Results with Live Webcast on March 5, 2025 - MyChesCo
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight - GlobeNewswire Inc.
Ocugen to Host Conference Call on Wednesday, March 5, 2025 - GlobeNewswire
Ocugen, Inc. to Host Conference Call for Q4 and Full Year 2024 Financial Results on March 5, 2025 - Nasdaq
Is QuantumScape Stock a Buy Now? - The Globe and Mail
Ocugen Earnings: Can This Gene Therapy Pioneer Turn Financial Corner in 2024? - StockTitan
Ocugen, Inc. (OCGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
European Commission nods at Ocugen’s gene therapy By Investing.com - Investing.com Nigeria
Chardan Capital Reaffirms Buy Rating for Ocugen (NASDAQ:OCGN) - MarketBeat
HC Wainwright Issues Positive Forecast for Ocugen (NASDAQ:OCGN) Stock Price - MarketBeat
UPCOMING OCGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
Why Ocugen (OCGN) Is Advancing Today - MSN
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen shares rise as H.C. Wainwright lifts price target to $8 - Investing.com Nigeria
Ocugen shares rise as H.C. Wainwright lifts price target to $8 By Investing.com - Investing.com South Africa
Expert Outlook: Ocugen Through The Eyes Of 4 Analysts - Benzinga
Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone Achieved! - MyChesCo
Ocugen, Inc. Announces Dosing Completion in the Phase 2 - GlobeNewswire
Ocugen Completes Dosing In Phase 2 ArMaDa Trial For OCU410 In Geographic Atrophy - Nasdaq
Ocugen announces dosing completion in Phase 2 ArMaDa clinical trial - TipRanks
Ocugen Completes Phase 2 Enrollment in OCU410 Clinical Trial for Geographic Atrophy Treatment - Nasdaq
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - GlobeNewswire
Revolutionary One-Time Gene Therapy Outperforms Monthly Injections in Macular Degeneration Trial - StockTitan
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
What's Going On With Ocugen Stock? - MSN
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
STATE STREET CORP Reduces Stake in Ocugen Inc by 62.93% - GuruFocus.com
Nasal COVID-19 vaccine based on WashU technology to enter U.S. clinical trials - WashU Medicine
Ocugen’s OCU400 Receives ATMP Classification from European Commission, Advancing Retinitis Pigmentosa Treatment - MSN
Ocugen's OCU400 Receives ATMP Classification from European Commission, Advancing Retinitis Pigmentosa Treatment - MyChesCo
European Commission nods at Ocugen's gene therapy - Investing.com India
Ocugen Announces Positive Opinion of European Medicines - GlobeNewswire
Ocugen gets positive EU opinion for ATMP classification for OCU400 - Seeking Alpha
Ocugen Says EMA Panel Issues Positive Opinion for Potential Eye Disease Treatment - Marketscreener.com
European Commission nods at Ocugen's gene therapy By Investing.com - Investing.com Australia
Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa - Ocugen
Ocugen, Inc. Receives Positive Opinion for OCU400 Advanced Therapy Medicinal Product Classification from European Commission - Nasdaq
Revolutionary Eye Disease Gene Therapy Advances: Ocugen Secures Fast-Track Status in Europe - StockTitan
Ocugen Files Secondary Stock Shelf -January 31, 2025 at 04:44 pm EST - Marketscreener.com
Ocugen Receives FDA Greenlight for Phase 1 Trial of Mucosal COVID-19 Vaccine - MSN
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):